secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tevogen Bio Holdings Inc. (TVGN)
CIK:        0001860871
Form:       8-K
Filed at:   2025-04-17T23:59:59+00:00
Accession:  0001641172-25-005236
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tevogen Bio inks related-party facility deal with CD8 for cell therapy production
--------------------------------------------------------------------------------

- Agreement with CD8 Technology Services (associated with >5% holder Dr. Manmohan Patel) for turn-key GMP cell therapy production facility.
- Tevogen to provide primary staff and operations; facility supports both pre-clinical research and GMP production.
- Initial term of 12 months, auto-renewing; specific costs, scope, and timelines to be set in future work orders.
- Agreement formalizes previously announced letter of intent and aligns with previously stated topline forecasts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860871/000164117225005236/0001641172-25-005236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860871/000164117225005236/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-005236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer